VAX24 -101 
 
 
CLINICAL STUDY PROTOCOL:  A Phase 1/2a, Randomized, Observer -Blind, Dose -
Finding, Controlled, Parallel -Group, Two -Stage 
Clinical Study to Evaluate the Safety, Tolerability, 
and Immunogenicity of a 24 -Valent Pneumococcal 
Conjugate Vaccine (VAX -24) in Healthy Adults 
Aged [ADDRESS_466339] IDENTIFIER:     [STUDY_ID_REMOVED] 
 
DOCUMENT DATE:     31 May 2022  
CLINICAL  STUDY PROTOCOL  
PROTOCOL  TITLE:  A Phase 1/2a, Randomized, Observer -Blind, Dose -Finding,  
Controlled, Parallel -Group, Two-Stage Clinical Study to Evaluate 
the Safety, Tolerability, and Immunogenicity of a 24- Valent 
Pneumococcal Conjugate Vaccine (VAX -24) in Healthy Adults 
Aged 18 to 64 Years 
PROTOCOL  NUMBER:  VAX24 -[ADDRESS_466340]:  
SPONSOR:  
VERSION:  
DATE:  VAX -24 
(24-valent Pneumococcal C onjuga te Vaccine) 
Vaxc
yte, Inc.  
825 Industria l R oad 
Suite 300 
San Carlos, CA [ZIP_CODE] [LOCATION_003] 
Te
l: [PHONE_7733] 
4.0 
31 May 2022  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  2 of 67 
  
 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  3 of 67 
  
 PROTOCOL  SIGNATURE  [CONTACT_372856]24 -101 
(Version 4.0) 
This Clinical Study Protocol document and all information provided to you, the Principal 
Investigator, related  to this protocol are the confidential  and proprietary  information  of Vaxcyte, 
Inc. (“Sponsor”) and are subject  to the terms  of the Confidential Disclosure Agreement  between 
you and Vaxcyte, Inc. 
 
 
By [CONTACT_31300], I hereby [CONTACT_372827]:  
I agree to abide by [CONTACT_372828],  Inc. Confidential Disclosure Agreement.  
I have read this protocol entitled, “A Phase 1/2a, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24- Valent  Pneumococcal  Conjugate Vaccine (VAX -24) in Healthy  Adults 
Aged 18 to 64 Years” in its entirety and I agree to conduct the study according to this protocol. Any changes  in procedure will only be made if necessary  to protect  the safety,  rights, or welfare 
of subjects. 
I agree to comply with the current  International Conference on Harmonisation Tripartite 
Guideline on Good Clinical  Practice in  addition to the appropriate FDA  Code of Federal 
Regulations (CFRs) and applicable state and local regulations. 
I agree to conduct the study in person or to supervise the study. 
I agree to ensure that all who assist me in the conduct of the study have access to the study 
protocol, including any amendments  thereto,  and are also made aware of their responsibilities  in 
meeting the foregoing obligations. 
 
 
 
Principal  Investigator  
(Print  Name)  
   
 
Title  
   
 
Signature  [CONTACT_372857],  Inc. and to keep  original for files.  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466341] OF  ABBREVIATIONS  .................................................................................................. 9  
PROTOCOL  SYNOPSIS  ...................................................................................................... 11 
1 INTRODUCTION  ...................................................................................................... 14 
1.1 Background and Rationale  ............................................................................... 14 
1.2 Name [CONTACT_372858]  ........................................... 16 
  
  
  
  
1.2.2 Rationale  for Dosage and  Route of Administration  .......................... 19 
2 OBJECTIVES  AND ENDPOINTS  ........................................................................... 20 
2.1 Primary  ............................................................................................................. 20 
2.2 Secondary  ......................................................................................................... 20
 
  
3 STUDY PLAN  ............................................................................................................ 22 
3.1 Study Design  .................................................................................................... 22 
3.2 Number of Study Participants  .......................................................................... 23 
3.3 Estimated  Study Duration  ................................................................................ 23 
3.4 Study Population .............................................................................................. 24 
3.4.1 Inclusion Criteria  ............................................................................... 24 
3.4.2 Exclusion Criteria  .............................................................................. 25 
4 STUDY VACCINE  ..................................................................................................... 27 
4.1 Investigational Vaccine  (VAX- 24) .................................................................. 27 
4.1.1 Active  Comparator  ............................................................................ 27 
4.1.2 Other  Supplies  ................................................................................... 28 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  5 of 67 
  
 4.2 Dose  Preparation  of Study Vaccines  ................................................................ 28 
4.3 Accountability  Procedures  for Study Vaccines  ................................................ 29 
5 STUDY PROCEDURES  ............................................................................................ 30 
5.1 Informed  Consent  ............................................................................................. 30 
5.2 Screening  .......................................................................................................... 30 
5.3 Medical  History  ................................................................................................ 31 
5.4 Physical  Examination  ....................................................................................... 31 
5.5 Vital Signs  ........................................................................................................ 32 
5.6 Laboratory Tests  ............................................................................................... 32 
5.6.1 Blood Volume  ................................................................................... 32 
5.6.2 Safety  Laboratory  Assessments ......................................................... 34 
5.6.3 Immune Response Assessments  ........................................................ 35 
5.7 Pregnancy  Testing  and Contraception  .............................................................. 35 
5.8 Randomization .................................................................................................. 36 
5.9 Study Vaccine Administration  ......................................................................... 37 
5.10 Acute Observation  ............................................................................................ 37 
5.11 Solicited  Adverse Events  ................................................................................. 37 
5.12 Unsolicited  Adverse Events  ............................................................................. 38 
5.13 Prior and Concomitant Medications  and Procedures  ....................................... 38 
5.14 Prohibite
d Medications  and Therapi[INVESTIGATOR_014]  ............................................................. 38 
5.15 Emergency  Unblinding  .................................................................................... 39 
5.16 Protocol Deviations  .......................................................................................... 39 
5.17 Dosing Errors  ................................................................................................... 39 
5.18 Study Completion: For Individual Subjects  ..................................................... [ADDRESS_466342]  Replacement  ........................................................................................ 40 
5.21 Study Completion: Overall  .............................................................................. 40 
6 STUDY PROCEDURES  BY [CONTACT_16990]  ......................................................................... 41 
6.1 Scheduled  Study Visits  .................................................................................... 41 
6.1.1 Screening  (-30 days to  Day  1) ........................................................... 41 
6.1.2 Day 1 ................................................................................................. 41 
6.1.3 Day 8 (+3  days)  ................................................................................. 42 
6.1.4 Day 15 (+3  days)  ............................................................................... 42 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  6 of 67 
  
 6.1.5 Day 29 (±  3 days)  .............................................................................. 42 
6.1.6 Months 3, 4, 5, 6 (90  to 180 days after Day 1  (± 5 days))  ................ 43 
6.2 Early  Discontinuation Visit .............................................................................. 43 
6.3 Unscheduled Visits  ........................................................................................... 44 
7 SAFETY  ...................................................................................................................... 45 
7.1 Definitions  ........................................................................................................ 45 
7.1.1 Adverse Event  ................................................................................... 45 
7.1.2 Solicited  Adverse Event  .................................................................... 46 
7.1.3 Unsolicited  Adverse Event  ................................................................ 46 
7.1.4 Serious Adverse Event  ...................................................................... 46 
7.2 Severity  Grading  .............................................................................................. 47 
7.3 Causality  Assessment  ....................................................................................... 47 
7.4 Follow-up of Adverse Events  ........................................................................... 48 
7.5 Reporting of Adverse Events  ........................................................................... 48 
7.5.1 Reporting Periods  .............................................................................. 48 
7.5.2 Documentation  .................................................................................. 49 
7.6 SAE  Reporting  ................................................................................................. 49 
7.7 Other  Events  Requiring Immediate  Reporting  ................................................. 51 
7.7.1 Pregnancy  ..........................................................................................
 51 
7.8 Medical  Monitor  ............................................................................................... 51 
7.9 Data Monitoring Committee  ............................................................................ 51 
7.10 Study Stoppi[INVESTIGATOR_1869]  ....................................................................................... 52 
8 DATA HANDLING .................................................................................................... 54 
8.1 Source Documentation  ..................................................................................... 54 
8.2 Retention  of Study Documentation  .................................................................. 54 
8.3 Data Monitoring  ............................................................................................... 54 
8.4 Electronic  Patient  Reported  Outcome Data ...................................................... 54 
8.5 Laboratory Data ................................................................................................ 55 
8.6 Audit Compliance  ............................................................................................ 55 
9 STATISTICAL  ANALYSIS  ...................................................................................... 56 
9.1 Sample  Size Calculation  ................................................................................... 56 
9.2 Treatment  Period  .............................................................................................. 56 
9.3 Treatment  Groups  ............................................................................................. 57 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  7 of 67 
  
 9.4 Populations for Analysis  .................................................................................. 57 
9.5 Demographic and  Baseline Characteristics  Analysis  ....................................... 58 
9.6 Safety  Analysis  ................................................................................................. 58 
9.6.1 Analysis of Extent of Exposure  ......................................................... 58 
9.6.2 Solicited  AEs ..................................................................................... 58 
9.6.3 Unsolicited  AEs ................................................................................ 59 
9.6.4 Combined Solicited  and Unsolicited  AEs ......................................... 60 
9.6.5 Analysis of Other  Safety  Data ........................................................... 60 
9.7 Immunogenicity Analysis  (50 to 64 years)  ...................................................... 60 
9.7.1 GMT/GMR  ........................................................................................ [ADDRESS_466343]  Confidentiality  ..................................................................................... 63 
10.5 Compensation for Injury  .................................................................................. 63 
10.6 Clinicaltria
ls.gov  .............................................................................................. 63 
10.7 Public Disclosure and Publication  Policy  ........................................................ 63 
10.8 Amendments ..................................................................................................... 63 
11 REFERENCES  ........................................................................................................... 64 
  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466344] OF  FIGURES  
 
Figure 1 Study Schema for Subjects 18 to 49 Years  of Age  ..........................................22 
Figure 2 Study Schema for Subjects 50 to 64 Years  of Age  ..........................................23 
Figure 3 Safety  Events Reporting Periods  ......................................................................49 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466345]  
eCRF  Electronic  Case  Report  Form  
eCRM  Proprietary  non-toxic  diphtheria  toxin  carrier  protein  used in VAX -24 
EDC  Electronic  Data  Capture  
ELISA  Enzyme -linked  immunosorbent  assay  
eSD Electronic  Source  Document  
FDA  US Food  and Drug  Administration  
GCP  Good  Clinical  Practice  
GMC  Geometric  Mean  Concentration  
GMFR  Geometric  Mean  Fold Rise 
GMR  Geometric  Mean  Ratio  
GMT  Geometric  Mean  Titer  
HBsAg  Hepatitis  B Surface  Antigen  
HBV  Hepatitis  B Virus  
HCG  Human  chorionic  gonadotropin  
HCV  Hepatitis  C Virus  
HIV EIA Human  Immunodeficiency  Virus,  Enzyme  Immunoassay  
ICF Informed  Consent  Form  
ICH International  Conference  on Harmonisation  
IEP Immunogenicity  Evaluable  Population  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466346]  
LLOQ  Lower  Limit  of Quantitation  
MAAE  Medically  Attended  Adverse  Event  
MedDRA  Medical  Dictionary  of Regulatory  Activities  
MSD  Meso  Scale  Discovery  
NOCI  New  Onset  of Chronic Illness  
NZW  New  Zealand  White  (species  of rabbits)  
OPA  Opsonophagocytic  assay  
pAMF  Para-azidomethyl -L-phenylalanine  
  
PCV  Pneumococcal  Conjugate  Vaccine  
PCV13  Prevnar® 13 
PCV20  Prevnar  20™ 
PD Pneumococcal  Disease  
PFS Pre-filled  Syringe  
PPV23  Pneumovax® 23 
PS Polysaccharide  
S. pneumoniae  Streptococcus  pneumoniae  
SAE Serious  Adverse  Event  
SAP Statistical  Analysis  Plan 
SMMP  Safety  Medical  Management  Plan 
SOC  System  organ  class 
S[LOCATION_003]R  Suspected  Unexpected  Serious  Adverse  Reaction  
TEAE  Treatment  Emergent  Adverse  Event  
VAX -24 24-valent  investigational  pneumococcal  conjugate  vaccine  
US United  States  
WHO  World  Health  Organization  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466347]  
VAX- 24 (24-valent  Pneumococcal  Conjugate  Vaccine)  
Names  of Comparator  Products  
Prevnar  20™ (20-valent  Pneumococcal  Conjugate  Vaccine;  PCV20)  
Study  Title  
A Phase  1/2a,  Randomized,  Observer -Blind,  Dose -Finding,  Controlled,  Parallel -Group,  Two-Stage  Clinical 
Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24- Valent Pneumococcal Conjugate 
Vaccine (VAX -24) in Healthy Adults Aged 18 to 64 Years  
Study  Number  VAX24 -101 
Study  Phase  1/2a 
Study  Sites  
Approximately  10 investigative  sites in the US 
Study  Objectives  and Endpoints 
Primary : 
The primary  objectives  are: 
• To evaluate the safety  and tolerability  of a single  injection  of VAX- 24 at three  dose levels 
administered to healthy adults 18 to 64 years of age.  
• To compare  the safety  of VAX -24 to that of PCV20  administered  to two control  groups:  1) subjects 
18 to 49 years of age receiving PCV20, and 2) subjects 50 to 64 years of age receiving PCV20.  
Primary  endpoints  are: 
• Percentage of subjects  reporting solicited  local  reactions  within  7 days after vaccination  (redness, 
swelling, and pain at injection site) in each age group.  
• Percentage of subjects  reporting solicited  systemic  events  within  7 days after vaccination  (fever, 
headache, fatigue, muscle pain, and joint pain) in each age group.  
• Percentage of subjects  reporting unsolicited  AEs within  1 month after vaccination  in each age 
group.  
• Percentage of subjects  reporting Serious  Adverse  Event  (SAE) and new onset  of chronic  illness 
(NOCI) within 6 months after vaccination.  
• Percentage of subjects  reporting  AEs with a new onset  or a worsening of a condition  that prompts 
the subject to seek unplanned medical advice at a physician's office, urgent care center, or 
Emergency Department (medically attended adverse event [MAAE]).  
Secondary : 
The secondary  objectives  are: 
• Safety: To assess laboratory value abnormalities and/or potentially clinically significant laboratory 
values  following  VAX- 24 at 3 dose levels  compared  to control  groups  receiving  PCV20  for subjects 
aged 50 to 64 years.  
• Immunogenicity:  To assess the induction  of antibody responses  by [CONTACT_210705]- 24 dose levels  compared  to 
control groups receiving PCV20 for subjects aged 50 to 64 years.  
The secondary  endpoints  include  the following:  
• Safety:  Percentage of participants  with laboratory value  abnormalities  and/or  potentially  clinically 
significant laboratory values at 1 month after vaccination.  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  13 of 67 
  
  
PCV20  will be administered  once,  by [CONTACT_52596],  at a dose of 0.5 mL, as packaged  by [CONTACT_3455].  
Treatment  and Duration  of Treatment  
Treatment  consists  of a single  IM injection  of VAX- 24 or a single  IM injection  of PCV20.  
Safety  Assessments  
Subjects will be evaluated for solicited and unsolicited adverse events (AEs), including injection site 
reactions  following  vaccine  administration.  Additionally,  changes  in laboratory values  (complete  blood count 
[CBC] and differential, chemistry; tests for HIV EIA, HBsAg, HCV Ab, urinalysis), NOCI, physical examinations, and vital signs following administration of study vaccines will be evaluated.  
Statistical  Methods  
Various  standard  statistical methods  will be employed  to analyze the data,  including  descriptive  statistics, 
linear models, and graphical displays.  
Summary statistics will consist of frequencies and percentages of responses in each category for discrete measures  and of counts,  means, medians, standard  deviations,  95% confidence  intervals,  and minimum  and 
maximum values for continuous measures, and will be presented by [CONTACT_204282].  
All calculated  fields  will be listed  in various  data listings  for review.  Additional  analyses  may be performed 
by [CONTACT_210678].  
Version  9.4M6 (TS1M6) or higher  of the SAS
® statistical software  package  will be used to provide  all 
statistical analyses.  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  14 of 67 
  
 1 INTRODUCTION  
1.1 Background and Rationale  
 
Streptococcus pneumoniae ( S. pneumoniae ) is the pathogen that causes pneumococcal disease 
(PD), classified as either non -invasive (otitis media, sinusitis, pneumonia) or invasive 
(bacteremia, meningitis). A persistent global incidence of PD, driven by [CONTACT_372829],  has resulted  in high morbidity  and mortality  worldwide. 
Pneumococci cause over 50% of all cases of bacterial meningitis in the US ( Gierke 2015 ). 
Mortality rates for invasive pneumococcal disease in the [LOCATION_002] range from 11% to 30% in adults ( Centers for Disease Control and Prevention 2018). The overall case- fatality rate for 
pneumococcal bacteremia is approximately 20% overall, increasing to 60% in the elderly (Centers for Disease Control and Prevention 2021 ). Pneumococcal pneumonia case fatality rates 
are also quite significant, estimated to be 5% to 7% overall with much higher rates also among elderly persons ( Gierke 2015 ). In a prospective population-based cohort study of adult residents 
in Louisville, Kentucky, from 1 June 2014 to 31 May 2016, mortality during hospi[INVESTIGATOR_40175] 6.5%, corresponding to an estimated  102,821 annual deaths  in the United  States  (Ramirez 2017).  
Despi[INVESTIGATOR_372805] 
(PCVs), due to the diversity of serotypes and the phenomenon of serotype replacement, a significant burden of PD remains which is currently not covered by [CONTACT_260791] 13
® (PCV13). In 
fact, just 28.6% of invasive PD cases in individuals ≥5 years old in the US in 2017 are due to serotypes included in PCV13, while non-PCV13 serotypes accounted for 71.4% (Varghese 2020). In the [LOCATION_002], a PCV vaccine covering all the serotypes in PCV13 and 
Pneumovax
® 23 (PPV23) would increase serotype coverage from  28.6% in individuals (>5 years 
old) for PCV13 to 69.6% for VAX- 24, respectively, as calculated from the data in Table 1 
(Varghese 2020).  
In August 2014, the Advisory Committee on Immunization Practices (ACIP) recommended use of PCV13  followed by [CONTACT_210681]23  for adults aged  ≥ [ADDRESS_466348] effects from 
pediatric PCV13 use might limit the utility of this recommendation ( Matanock 2019).  
 
With  the recent  FDA  approval of Prevnar20™ (PCV20),  a 20- valent  pneumococcal  conjugate 
vaccine, the ACIP reconvened in October  2021 to  revise their recommendation to use  PCV20 
without a subsequent dose of PPV23 or use Vaxneuvance™ (PCV15) followed by [CONTACT_210681]23. 
 
Even with the approval of PCV20, due to the diversity of serotypes and the phenomenon of serotype replacement, a significant burden of PD remains which is currently not covered by [CONTACT_372830]20. For example,  currently  PCV20  is estimated  to cover  just over half the serotypes  causing 
invasive PD in those ≥65 years of age. The estimated incremental coverage a 24- valent  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  15 of 67 
  
 pneumococcal conjugate vaccine could contribute above PCV20 varies between 8 to 15% in 
adults ( Gierke 2021 ). However, adding valency to existing PCVs using conventional 
technologies has proven difficult, for several reasons. First, data show that as more carrier protein/polysaccharide (PS) conjugates are added  to existing  PCVs,  immune  responses to the PSs 
often  decrease  due to the cumulative  amount of carrier  protein, which  immunologically  competes 
with the PS antigens ( Dagan 2010), as most recently seen with PCV20 (Prevnar 20 Package 
Insert  2021). Second, conjugating additional PSs to a carrier  protein molecule  may mask  existing 
T-cell epi[INVESTIGATOR_372806]. In the PCV13  
carrier protein CRM197, approximately 20% of the 39 lysine residues border relevant T- cell 
epi[INVESTIGATOR_322] ( Choe 1992; Diethelm-Okita 2000; Raju 1995). Since conventional conjugation 
chemistry heterogen eously conjugates PSs to lysine residues independent of their proximity to 
T-cell epi[INVESTIGATOR_322], a bound PS  may block the presentation  of a T- cell epi[INVESTIGATOR_372807], 
thus preventing the induction of a T- cell response. Meanwhile, the B -cell epi[INVESTIGATOR_372808],  increasing  B-cell competition 
for any available T -cell help. The masking of these critical epi[INVESTIGATOR_210655] a 
T-cell dependent immune response and negates the benefit of the carrier protein. This competition for T-cell help diminishes the immune response to the PS antigen and is believed to result in the phenomenon known as carrier suppression ( Dagan 2010).  
To address this issue, Vaxcyte is developi[INVESTIGATOR_372809], VAX-24, using a novel process that combines site -specific conjugation to the carrier protein and a highly efficient conjugation 
chemistry. Vaxcyte employs a cell -free protein synthesis platform to insert the  non-native amino 
acid para-azidomethyl-L-phenylalanine (pAMF)  into eCRM,  a recombinant version of CRM197. 
These pAMF residues serve as PS conjugation sites, and are inserted in place of purposefully selected lysines, such that critical T -cell epi[INVESTIGATOR_372810] T -cell-dependent immune response. 
 
This first -in-human trial VAX24-101 is a dose-finding Phase 1/2a that will examine the safety, 
tolerability, and immunogenicity of the VAX-[ADDRESS_466349] (DP) vaccine at three different strengths, and the results will be compared to those for the currently recommended regimen of PCV20. The study will be  conducted in healthy adult populations: aged 18 to 49 years and 50 to 
64 years.  The trial will be enrolled  in two sequential  stages:  a Phase [ADDRESS_466350].  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  16 of 67 
  
 1.2 Name  [CONTACT_372859]-24 consists of capsular  polysaccharide antigens  of Streptococcus pneumoniae  
(S. pneumoniae) serotypes 1, 2, 3, 4, 5, 6A,  6B, 7F,  8, 9N,  9V, 10A, 11A, 12F,  14, 15B, 17F,  
18C, 19A, 19F, 20B, 22F, 23F, and 33F, with each of the 24 polysaccharides  (one from  each 
serotype) individually conjugated in a site-specific manner to a novel and proprietary 
recombinant diphtheria carrier protein referred to as eCRM, and mixed with aluminum phosphate (ALPO). 
 
VAX-24 is described  further in Section  4. 
 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  17 of 67 
  
 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  18 of 67 
  
  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  19 of 67 
  
 1.2.2 Rationale fo
r Dosage and Route  of Administration  
 
The dosages of VAX-24 are 1.1 mcg/dose (low), 2.2 mcg/dose (mid), or 2.2/4.4 mcg/dose 
(mixed), where potency of the formulated vaccine is determined by [CONTACT_372831]. Based on the body o f literature available 
on conjugated pneumococcal vaccines, the closest comparison to VAX-24 to establish a dose range was PCV20. Each ‘Mid’ dose is formulated to contain a similar quantity of Streptococcus pneumoniae polysaccharides as that of PCV20, the current standard of care. The ‘Mixed’ dose includes a similar quantity as the ‘Mid’ with the exception of inclusion of a higher amount for seven  serotypes: two important epi[INVESTIGATOR_372811] (3, 19A),  and five shown  to 
exhibit a dose-dependent response during the development of PCV13 ( Varghese 2020, 
Jackson 2007). By [CONTACT_372832] -specific conjugation to the CRM protein carrier thereby 
[CONTACT_372833] -to-eCRM ratio and enhancing overall T -cell epi[INVESTIGATOR_210659], VAX-24 may 
be more  potent than PCV13  and so a dose roughly half  that of PCV13  has also been  included in 
this study. 
These doses are below or approximately equivalent to those used in the nonclinical toxicology 
studies.  
 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  20 of 67 
  
 2 OBJECTIVES  AND ENDPOINTS  
2.1 Primary  
 
The primary  objectives are:  
 
• To evaluate the safety  and tolerability  of a single injection  of VAX -24 at  three dose 
levels administered to healthy adults 18 to 64 years of age.  
• To compare the safety  of VAX-24 to that of PCV20  administered  to two control groups:  
1) subjects  18 to 49 years of age;  and 2) subjects  50 to 64 years of age.  
 
Safety and tolerability will be assessed by [CONTACT_372834]  (AEs),  unsolicited  AEs,  serious adverse events  (SAEs),  new onset of 
chronic illness (NOCI), and medically attended adverse events (MAAEs):  
• Percentage of subjects  reporting solicited  local  reactions  within  7 days after vaccination 
(redness, swelling, and pain at injection site) in each age group 
• Percentage of subjects  reporting solicited  systemic  events  within  7 days after vaccination 
(fever, headache, fatigue, muscle pain, and joint pain) in each age group 
• Percentage of subjects  reporting unsolicited  AEs within  1 month after vaccination in each 
age group 
• Percentage of subjects reporting SAEs  and NOCI  within  6 months after  the vaccination  
• Percentage of subjects  reporting AEs  with  a new onset or a worsening of a condition that 
prompts the subject  to seek unplanned medical  advice at a physician's office,  urgent care 
center, or Emergency Department (MAAE).  
2.2 Secondary  
 
The secondary objectives are:  
 
• Safety:  To assess laboratory value abnormalities  and/or potentially  clinically  significant 
laboratory values following VAX-24 at 3 dose levels compared to control groups 
receiving PCV20 for subjects aged 50 to 64 years. 
• Immunogenicity: To assess the induction of antibody responses by [CONTACT_210705]-24 dose levels 
compared to control groups receiving PCV20 for subjects aged 50 to 64 years. 
 
The secondary endpoints include  the following:  
 
• Safety:  Percentage of participants  with  laboratory value abnormalities  and/or potentially 
clinically significant laboratory values at 1 month after vaccination.  
• Immunogenicity: 24 VAX-24 Pneumococcal  serotype- specific  OPA  geometric mean  titer 
(GMTs) at 1 month after vaccination (Day 29). 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  22 of 67 
  
 3 STUDY PLAN  
3.1 Study  Design  
 
This Phase 1/2a parallel -group, randomized, observer-blind study is to be conducted in two 
populations of healthy  adults,  18 to 49 years  of age and 50 to 64 years  of age.  Subjects  will be 
randomly assigned in a 1:1:1:1 ratio to receive either VAX- 24 at one of three dose levels  
(1.1 mcg, 2.2 mcg, or 2.2/4.4 mcg)  or the comparator  (PCV20).  
 
A Phase 1 cohort of 64 subjects (16 from each VAX-24 dose group and 16 from the comparator 
group) aged 18 to 49 years will be enrolled initially ( Figure 1 ). Safety labs will be evaluated at 
screening  for eligibility  including pregnancy  test for females  of childbearing potential and safety 
labs will be repeated [ADDRESS_466351]-vaccination, with safety data (limited to SAEs, NOCIs, and MAAEs)  collected  up to [ADDRESS_466352] 
blood samples drawn for safety labs at Screening and Day 29 (refer to Section 5.6). A defined safety review of data (AEs) through [ADDRESS_466353]-vaccination will occur by [CONTACT_82571] (DMC) before proceeding with enrollment of the Phase 2 subjects. 
Figure 1 Study  Schema  for Subjects  18 to  49 Years of Age 
 
 
 
 
A Phase 2 cohort of 800 subjects in the 50- to-64-year-old age range (200 in each arm) will be 
split into  4 groups ( Figure 2).  A minimum of [ADDRESS_466354]- 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466355] blood samples  drawn  for safety  labs and 
immunogenicity analysis (OPA and IgG) at Screening and Day 29 (refer to Section 5.6).  
Figure [ADDRESS_466356] an additional 32 mL of 
blood collected  per blood draw  to be processed  for peripheral  blood mononuclear cells  (PBMCs) 
to further characterize the immune response to VAX -24. Additional serum samples collected 
from  all subjects  aged  [ADDRESS_466357] 864 healthy  US adults who meet  the eligibility 
criteria listed in Section 3.4. 
 
Approximately 64 eligible  subjects  aged  18 to 49 and  800 subjects  aged  50 to  64 years  will be 
enrolled.  
3.3 Estimated  Study  Duration  
 
The Screening  period is 30 days, treatment  and observation period is from  Day  1 to Day 29, and 
the follow-up period is through Day 180 (6 months from study vaccination). The maximum possible study duration for an individual is 210 days. 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466358] meet  all of the following criteria  in order to be enrolled:  
 
1. Male or female age 18 to 49 years  (inclusive) for the Phase 1 group, or 50 to 64 years 
(inclusive) for the Phase [ADDRESS_466359] be within  the central  laboratory normal limits1 prior to 
study enrollment. Minor abnormalities are considered acceptable if not clinically 
significant.  
Note:  Laboratory values  lower  than the normal range may be acceptable  if the Principal 
Investigat[INVESTIGATOR_1660] [INVESTIGATOR_1660] a designated licensed clinician determines that these laboratory findings 
are not clinically significant. The HIV 1/2 antibody/antigen test, Hepatitis B surface 
antigen (HBsAg), and Hepatitis C virus (HCV) antibody must be non- reactive.  
6. Willing  to have blood samples  collected,  stored  indefinitely,  and used for research 
purposes.  
7. Able  to provide proof of identity  to the satisfaction  of the study staff completing  the 
enrollment process. 
8. Negative pregnancy  test (urine  and serum)  for women  of childbearing potential.  
Non-pregnant, non- lactating  females  must also meet  one of the following criteria:  (a) no 
reproductive potential because of menopause (one year without menses)  or because  of a 
hysterectomy, bilateral oophorectomy, or tubal ligation; (b) subject agrees to be heterosexually inactive at least 14 days prior to vaccination and throughout the duration of the study; or (c) agrees to consistently practice contraception at least 7 days prior to 
enrollment and throughout the duration of the study by [CONTACT_7053]: 
condoms, male or female, with or without a spermicide, diaphragm or ce rvical cap with 
spermicide,  intrauterine  device,  contraceptive pi[INVESTIGATOR_43516],  Norplant, Depo -Provera,  or 
other FDA approved contraceptive method, or a female with a male partner that has previously undergone a vasectomy. 
 
 
1 See Central  Laboratory  Manual  for normal  values.  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  25 of 67 
  
 3.4.2 Exclusion Criteria  
 
Subjects  who meet  any of the following criteria  cannot be enrolled:  
 
1. Previous pneumococcal disease (either  confirmed or by [CONTACT_6270]-reporting).  
2. Previous receipt  of a licensed  or investigational pneumococcal  vaccine.  
3. Receipt  of any investigational study product within  [ADDRESS_466360](s) while on study. 
4. Planned  or actual  administration  of any licensed  vaccine during the period starting 
30 days before enrollment into the study through Day 29. 
5. Physical  examination  indicating  any clinically  significant medical  condition. 
6. Body Temperature  > 38.0°C (> 100.4°F) or acute  illness  within  3 days prior to study 
vaccination (subject may be rescheduled).  
7. Seropositive to HIV,  HCV,  or HBsAg.  
8. History  of severe  allergic  reaction  with generalized  urticaria,  angioedema,  or 
anaphylaxis.  
9. Female who  is breast -feeding or planning to  become pregnant during study participation.  
10. Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or platelet disorder requiring special  precautions) or significant bruising or bleeding difficulties  with 
IM injections or blood draws. 
11. Any other chronic or clinically significant medical condition that, in the opi[INVESTIGATOR_871], would jeopardize the safety or  rights of  the subject or confound evaluation 
of the study vaccine, including but not limited to: diabetes mellitus type I, untreated 
hypertension, chronic hepatitis; or clinically  significant forms  of: drug or alcohol abuse, 
asthma, autoimmune disease, psychiatric disorders, heart disease, pulmonary disease, neurologic disease, cancer, or any known or suspected impairment immune function. 
12. Any medical,  psychiatric, or social  condition that, in the judgment of the investigator,  is a 
contraindication to protocol participation or impairs a subject’s ability to give informed consent.  
13. Received  blood or blood product (including Immune  Globulin IV) within  90 days prior to 
enrollment into the study. 
14. Received  systemic  cor
 ticosteroids for ≥ 14 consecutive days and  has not completed  
treatment  ≤30 days prior to  enrollment into  the study.  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  26 of 67 
  
  
15. Receiving  immunosuppressive therapy, including chemotherapeutic agents  used to treat 
cancer or other conditions, immunostimulants, and treatments associated with organ or 
bone marrow transplantation, or autoimmune disease. 
16. History  of malignancy  ≤5 years  before enrollment,  except  for adequately  treated  basal  
cell or squamous cell skin  cancer  or in  situ cervical cancer.  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  27 of 67 
  
 4 STUDY VACCINE  
4.1 Investigational Vaccine (VAX- 24) 
 
VAX-24 is the Sponsor’s research name [INVESTIGATOR_8178] a Pneumococcal Conjugate Vaccine. VAX-24 
consists of capsular polysaccharide antigens of Streptococcus pneumoniae (S. pneumoniae) 
serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 
20B, 22F, 23F, and 33F, with each of the 24 polysaccharides (one from each serotype) individually conjugated in a site-specific  manner to a proprietary  non-toxic diphtheria carrier 
protein referred to as eCRM, and mixed with ALPO. 
 
 
Each vial i
s filled to deliver a single 0.5 mL (extractable volume) dose of VAX-24 vaccine for 
IM administration, with no preservative.VAX-24 is manufactured by [CONTACT_210684] (Switzerland) and will be supplied at three strengths in single- use 2 mL glass vials. The vial is 
sealed with a 13 mm gray bromo butyl rubber stopper with FluroTec
® coating on the side in 
contact [CONTACT_372835] -24 DP. The stopper is capped with a 13 mm crimped aluminum seal with a 
flip-off white cap for Low strength, a blue cap for Mid strength, and a green cap for the Mixed 
strength.  
The three different  strengths of VAX-24 will be identified  as: 
 
• Low,  1.1 mcg  of Total  PS/dose per serotype  
• Mid, 2.2 mcg  of Total  PS/dose per serotype  
• Mixed, 2.2 or 4.4 mcg of Total PS/dose per serotype. Conjugate Drug Substance 
serotypes 3, 6B, 7F, 9V, 18C, 19A, and 19F are present  at the higher level,  with  the other 
[ADDRESS_466361] be stored in a temperature-controlled refrigerator at 2°C to 8°C with 
controlled, limited  access,  and accessible to authorized  personnel only. The temperature should 
be monitored by [CONTACT_372836]/minimum temperature readings 
inside the vaccine storage unit at least once each working day.  
4.1.1 Active Comparator  
 
Prevnar 20™ (PCV20), 20-valent pneumococcal conjugate vaccine is a sterile suspension of saccharides of the capsular antigens of S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F individually linked to non-toxic diphtheria CRM197 protein. PCV20 is manufactured by [CONTACT_100857], LLC (subsidiary of [COMPANY_007] Inc.) and is commercially available in the US. Each 0.5 mL dose of the vaccine  is formulated  to contain  approximately 2.2 mcg of each S. pneumoniae serotypes 1, 3, 4, 
5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F; 4.4 mcg of the 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  28 of 67 
  
 polysaccharide from  serotype 6B; 51 mcg CRM197  carrier  protein; and 100 mcg  polysorbate 80, 
295 mcg succinate buffer, 4.4 mg sodium chloride, and 125 mcg aluminum as aluminum 
phosphate adjuvant. PCV20 pre-filled syringe (PFS) are to be stored at 2°C to 8°C (36°F to 46°F), as required by [CONTACT_3455]. 
 
Refer  to PCV20  Package Insert  for clinical  dosage and  administration,  storage and handling, 
contraindications, warnings and precautions, and summary of clinical trial results. 
4.1.2 Other Supplies  
 
The following supplies are provided by [CONTACT_372837]:  
• 1 mL BD Luer -Lok™ Syringe sterile,  single use polycarbonate  
• 25 Gauge BD™ Needle 1 inch  single use, sterile  
• 25 Gauge BD™ Needle 1  1/2 inch  single use, sterile  
4.2 Dose  Preparation  of Study  Vaccines  
 
A central  supply depot will provide study vaccines  and ancillary  supplies.  
 
Unblinded site personnel will manage all aspects of the vaccine inventory; prepare the vaccine 
for administration; administer  the vaccine  and active  comparator to study subjects;  and store  and 
monitor the vaccine in a secure area and maintain all accountability documentation. All study site personnel who complete subject assessments will be blinded to the vaccines being administered to study subjects. Unblinded site personnel will be trained in all aspects of  vaccine 
management, preparation, and administration, and will be provided a Pharmacy Manual 
regarding such procedures. 
 
All study vaccines are parenteral drug products that should be inspected visually for particulate 
matter and discoloration prior to administration. The product should not be used if particulate matter or discoloration is found. VAX-[ADDRESS_466362] be brought to room temperature and administered  ≥ 10 minutes and ≤ [ADDRESS_466363] be administered within ≤ 60 minutes. Detailed instructions on packaging, preparation, administration, and accountability are found in the VAX24-101 Pharmacy Manual. 
 
PCV20  will be supplied to the clinical  sites as single -use PFS packaged  by [CONTACT_3455]. 
PCV20  should be administered  by [CONTACT_372838]24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  29 of 67 
  
 refrigeration.  Preparation  and administration  instructions  are found in the PCV20  Prescribing 
Information (manufacturer’s package insert) and should be adhered to. 
 
Each  vaccine is administered  IM in the deltoid  muscle  of the upper arm as a single dose of 
VAX-[ADDRESS_466364] maintain and retain accurate, original site records of study material inventory as well as 
copi[INVESTIGATOR_372812]. 
 
Drug accountability information will be collected in electronic source document format for tracking  study vaccines  (eg, date material  was received,  dispensed to individual subjects,  and 
amount used and unused on site etc). 
 
Each  site must keep  all used  and unused study material until the unblinded CRA  has performed 
vaccine accountability and arranges return to the central repository vendor or gives instruction for used vaccine  disposal. Expi[INVESTIGATOR_372813]. 
 
Shipment of vaccine will be contingent on enrollment at the study sites.  Detailed  instructions on 
packaging, preparation, administration, and accountability are found in the VAX24-101 Pharmacy Manual.  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  30 of 67 
  
 5 STUDY PROCEDURES  
 
Source documents and source data will be captured electronically, meeting the same elements of 
data quality and integrity (ALCOA: attributable, legible, contemporaneous, original, and 
accurate) as paper records. Data will be collected into a fully validated system, with changes to data captured by [CONTACT_372839]. The clinical trial site will use their own tablets or la ptops 
to directly record subject data and clinical observations into electronic forms. Designated site staff will receive access to the system after appropriate training. As the trial uses electronic source documents as the original point of data capture, there is no additional data transcription step for the site to enter  the CRF  data into the application, except  for the signed informed  consent 
form (ICF).  
Some data may be captured via paper and subsequently transcribed into the eSource system. These source data will be verified  by [CONTACT_372840] (ie, paper,  local  electronic system,  etc) documented before the start of the trial. Copi[INVESTIGATOR_372814] -time access.  
 
Remote monitoring of original electronic source records will be performed, but on- site 
monitoring would occur  for review  of any paper  source documents and their transcription  into 
the system, etc.  
5.[ADDRESS_466365] (IRB) -approved ICF. For further details on informed consent, refer to 
Section  10.3. 
 
5.2 Screening  
 
Screening  procedures  are listed  in the Schedule of Events ( APPENDIX A ). 
 
Upon entry  of a subject into the Screening  Form  within  the electronic data capture (EDC) system, 
each Subject  will be automatically  assigned  a unique Subject  identifier.  This Subject  ID will be in 
the following format: 
 
Each  subject  who signs an ICF will receive  a sequential  three-digit identification  number unique 
to the site (eg, 001, 002…). When screening information is subsequently entered into the EDC, each subject will be assigned a subject identification number with the following format: 
 
VAX24 -101 ─ two-digit site  number ─ three- digit identification  number  
 
An example  of a subject identification  number is: VAX24 -101 – 01 – 001. Subject  numbers will 
also be sequential since screen -failed subjects will be entered into the EDC system.  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466366] the reason(s) for screen failure for all subjects who receive a 
subject identification number within the EDC system. Sites may elect to use a pre -screening 
consent form,  and maintain  a pre-screening  log for those subjects  contact[CONTACT_372841]. 
 
Re-screening  
 
A subject who meets exclusion criterion of having a current acute febrile illness at the time of 
scheduled enrollment may be re-screened after resolution of the acute illness. A subject who 
meets exclusion criteria of  taking an investigational product, licensed vaccines, or medications 
(ie, systemic  corticosteroid)  within 30 days (or blood or blood product within 90 days) prior to 
Day [ADDRESS_466367] number. 
5.3 Medical  History  
 
Medical  history information  will be collected  from  subjects  at the Screening  Visit and confirmed 
at the Day 1 (Baseline) Visit. Medical history will include (but not be limited to) demographic 
information, current and past medical conditions, and prior and concomitant medications taken within [ADDRESS_466368]’s medical records and/or state- mandated vaccine registry are 
available,  the site is required  to maintain  this documentation as part of the eligibility  review.  
5.4 Physical Examination  
 
A complete  physical examination  will be performed  on subjects  during the Screening  visit. 
The examination should include: 
• Height  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  32 of 67 
  
 • Body weight  
• Vital signs  
• General  appearance  
• Eyes -ears-nose-throat  
• Head -neck 
• Lungs -chest  
• Heart  
• Abdomen  
• Musculoskeletal  
• Lymph nodes  
• Skin 
• Extremities  
• Neurological  
 
A physical exam  may be performed  on subjects  at additional time points if indicated  by [CONTACT_210691].  
5.[ADDRESS_466369] is  up to ~54 mL,  
 
Phlebotomy will observe the American  Red Cross  limit of no more  than 450 mL in any 8-week 
period.  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  33 of 67 
  
 Unscheduled laboratory tests may be performed if indicated by a change in medical condition 
(including clinically  significant abnormal values).  The volume to be collected  will be appropriate 
to the tests performed. 
 
NOTE:  ALL  CRYOVIALS  SHOULD  BE FROZEN  AND STORED  AT -20o C OR 
COLDER AND SHIPPED ON DRY ICE.  
Table 3 Blood Collections  
 
Study  Day Blood 
volume (mL) Laboratory Tests  Tube  Type/volume  Minimum # of [ADDRESS_466370] 3.5 mL N/A 
  Serology  (HIV,  HCV, 
HBsAg)  
Serum  HCG (females 
only)  [ADDRESS_466371] 3.5 mL 
(+5 mL for confirmation)  
Run off SST tube  
Day 1 17 (or 33)* Immunogenicity*  [ADDRESS_466372] 4 
Day 29 5.5 Hematology  1 EDTA  2 mL N/A 
 22.5 (or Clinical  Chemistry  [ADDRESS_466373] 3.5 mL N/A 
 38.5)*  Immunogenicity*  [ADDRESS_466374]  tube 4 
Total: ~20 mL for subjects aged  18 to 49 years;  ~54 mL for subjects aged  50 to 64 
years;  30 
Abbreviations:  HBsAg  = Hepatitis  B surface antigen;  HCG  = human chorionic  gonadotropin;  HCV  = Hepatitis  C 
virus;  HIV = human  immunodeficiency  virus;  N/A = not applicable;   
 
* Immunogenicity and PBMC sample  collection  would only be collected  from  subjects  aged  50 to 64 years  old. 
 
Samples  are obtained during the trial according  to APPENDIX A . At each time point, blood is 
collected in the appropriate blood tube(s). 
 
Upon review and approval by [CONTACT_456], the clinical sites will adhere to their standard 
operating procedures  for collecting  and storing PBMCs.  Upon receipt  at the central  laboratory, 
these samples will be stored in liquid nitrogen. 
 
To minimize  the impact  of lost or damaged  shipments, the frozen  serum   samples  will 
be sent in separate consignments (primary, backup) to the central laboratory. 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  34 of 67 
  
 Further details  regarding  specimen  collection,  processing, and shippi[INVESTIGATOR_210661].  
5.6.2 Safety  Laboratory Assessments  
 
Biological samples  will be collected  for the following clinical  laboratory tests and shipped to the 
central laboratory for analysis:  
 
Hematology: Hemoglobin, White  blood cell count (absolute), Neutrophils (absolute), 
Eosinophils (absolute), Platelet count 
 
Clinical Chemistry:  Albumin, Alkaline  phosphatase, Alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), Bilirubin (total and direct), Blood urea nitrogen, 
Calcium, Carbon dioxide, Chloride, Cholesterol and triglycerides, Creatinine, Glucose (random), Gamma-glutamyl transferase (GGT), Lactate dehydrogenase, Phosphate, Potassium, Sodium, Total serum protein, Uric acid 
 
Urinalysis:  Specific gravity,  pH, Glucose,  Protein  (Total),  Ketones,  Bilirubin, 
Urobilinogen, Hemoglobin, Leucocyte esterase, Nitrite 
 
Serology: HIV 1/2 antibody/antigen test, HBsAg,  Hepatitis  C virus antibody (HCV  Ab) 
 
Pregnancy:  Serum  test at Screening  visit only  
 
Urine  pregnancy  tests  will be conducted at  the site using  a dipstick  before  vaccination.  
 
Screening  safety  lab results  are required  for subject eligibility  in order to be enrolled  in the study 
at Day 1. Screening safety labs will be used as baseline if a subject meets eligibility for enrollment into the study. Screening laboratory tests reported as minor abnormalities are considered acceptable if not clinically significant (eg, MCV). Repeating the screening tests once is permitted for out-of-range values, provided there is an alternative explanation for the out-of- range value.  This alternative  explanation  should be documented in the subject’s  source 
documents.  
 
Unscheduled laboratory tests will be performed if indicated by a change in medical condition (including clinically  significant abnormal values).  The volume to be collected  will be appropriate 
to the tests performed. The toxicity grading scales for clinical laboratory values ( FDA 2007 ) 
must be used when  assigning severity  to an out-of-range laboratory value;  however, not all  out of 
range laboratory values are considered AEs and need to be evaluated according to Section 7.1.1, Adverse Events.  
 
Further details  regarding  specimen  collection,  processing, and shippi[INVESTIGATOR_210661].  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466375] assays, OPA and multiplexed Meso Scale Discovery (MSD). 
 
The OPA assay has been developed and qualified by [CONTACT_210692], a GCP- compliant central 
laboratory, to analyze the [ADDRESS_466376] by [CONTACT_210693] (marking pneumococci for destruction) for phagocytosis ( Burton and Nahm 2006).  
 
The MSD  assay  has been  developed and qualified  by [CONTACT_372842] [ADDRESS_466377]  multiple  antigens and has been  used to evaluate responses to 
various pneumococcal conjugate vaccines ( Marchese 2009 , Goldblatt 2011, Feyssaguet 2019, 
and Nolan 2020).  
 
The immune responses (as assessed by [CONTACT_372843]) against the 20 polysaccharide antigens common to  PCV20  and VAX-24 (1,  3, 4,  5, 6A, 6B, 7F,  8, 9V,  10A,  11A, 12F, 14, 15B,  
18C, 19A, 19F, 22F, 23F and 33F) will be compared  in the various treatment groups (VAX-24 at 
3 different dose levels, and the comparator vaccine), and the 4 incremental polysaccharide antigens contained in VAX-24 (2, 9N, 17F and 20B) will be evaluated separately. 
 
Immunogenicity samples will be collected for subjects aged 50 to 64 years only.  
 
5.7 Pregnancy  Testing  and Contraception  
 
Female subjects of childbearing potential will undergo a serum Human Chorionic Gonadotropin 
(HCG)  pregnancy  test at Screening  and a urine  pregnancy test prior to each injection.  The subject 
must have a negative pregnancy test prior to study vaccine administration.  The Investigator must 
report any pregnancies as described in Section 7.7.1. Female subjects of childbearing potential 
must also use an acceptable method of contraception from prior to Day 1 through Day 180 (throughout the study). The Investigator must confirm that contraception methods were initiated prior to Day 1 (eg, hormonal contraception) to be considered fully effective. 
 
For reporting a pregnancy, refer  to Section  7.7.1, Pregnancy.  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466378] or designee will prepare the treatment assigned and dispense the appropriate treat ment to the Unblinded 
Administrator for administration.  
 
Randomization will be 1:1:1:1 for the four treatment groups within  each age group (18 to 49, 
50 to 64). Within the 50 to 64 year group, subjects will be further stratified into two groups: 50 to 59 and 60 to 64 years.  The total sample  size expected within  the 50 to 64 year age group is 
800 subjects; there will be a minimum number of 100 subjects in the 60 to 64 year age group (25 per treatment arm). See Section 9.[ADDRESS_466379]  will be considered enrolled  once a randomization  number has been  assigned  within  the 
EDC system. The study will be conducted as an observer-blind study. Neither subjects, clinical site evaluators including the investigators, nor the Sponsor will know subjects’ individual treatment assignments until all subjects have completed their par ticipation in the study and the 
database has been cleaned and locked.  
 
The following safeguards  will be employed to  reduce the risk  of inadvertent unblinding:  
 
• Each clinical site is required to have a blinding plan that outlines its process on blinding 
the subject in situations such as administration of IM injection with different syringe types, transfer of study vaccine to the clinic room for administration, providing initial training  and reminders  to the subjects  to not disclose  their experiences  with the injections 
except with unblinded study staff. 
• No Sponsor personnel other than the designated  unblinded monitor(s) and third -party 
unblinded biostatistics and programming staff will have access to the randomization treatment assignments.  
• Should any subject or blinded staff member become inadvertently unblinded, the Investigator will promptly (within 24 hours of the Investigator’s awareness of the error) disclose the event  to the Sponsor clinical  study manager  and medical  monitor in a blinded 
fashion (disclosing only subject number, not treatment) so that corrective action can be initiated. The unblinding sequence of events will be documented as a protocol deviation and retained as source documents. See Section 5.15 for details on Emergency  
Unblinding.  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  37 of 67 
  
 5.9 Study  Vaccine Administration  
 
On Day 1 before  study vaccine administration,  the medical  history, including physical exam  (if 
indicated by [CONTACT_210697]) and vital signs, and concomitant medications will be 
collected and updated in the subject file, serum  samples will be 
collected, and females of childbearing potential must have a negative urine pregnancy test. Immediately  prior to study vaccine administration,  staff should recheck  subject  eligibility.  Once 
these procedures are performed, study vaccine will be administered. All doses of study vaccine are 0.5 mL in volume and are administered by [CONTACT_356487] a Sponsor-provided 1 mL syringe and 25 gauge 1” (or 1.5”, at the Investigator’s discretion) needle as described above or PCV20 PFS, using universal precautions and sterile technique. All injections will be administered into the deltoid muscle. Injections will be administered by [CONTACT_372844]. 
5.[ADDRESS_466380] the details in their electronic diary at the end of their day.  
 
Allergic reactions to the study vaccine are possible; therefore, appropriate drugs and medical equipment to treat acute anaphylactic reactions  must be immediately  available  and a medically 
qualified study team member trained to recognize and treat anaphylaxis must be present in the clinic during the entire post-dosing monitoring period. 
5.11 Solicited  Adverse Events  
 
Solicited AEs will be collected for 7 days after vaccine administration, starting on Day 1. 
Solicited  AEs for this study  are local  events  of pain,  erythema (redness)  and edema (swelling)  at 
the injection site, and systemic events of oral temperature ≥ 100.4ºF, fatigue, headache, muscle pain, and joint pain. 
 
Subjects  will be trained  to complete  a diary  via IBM’s  ePRO  system.  This system  is accessed  via 
a secure URL and will be used to observe, measure, and record these solicited AEs. A digital thermometer  will be  provided to the subject to measure oral temperature  each day, and it is to be 
recorded daily in the diary. To record injection site local reaction, a ruler will be provided to the subject to measure the diameter of redness and swelling at the largest point of the reaction each day; it is to be recorded daily in the diary. 
 
Study staff will be provided with a Reference Guide for instructing subjects on accessing the IBM  ePRO  system.  Each  user  will be provided with login credentials  and a temporary  password. 
The IBM ePRO system is web -based and accessed via a secure URL.  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466381]’s clinic visit. The electronic diary will serve as the primary source document and data will be automatically  integrated  into the subject  visit Solicited  AE form  in the 
EDC platform for site staff view -only access. The Investigator will then assess all recorded 
solicited events for severity and relatedness. Severity will be graded according to the FDA Toxicity Grading Scale ( FDA 2007). The results of the Investigator’s assessment, if different 
from  the subject’s  entry, will  be recorded  in a separate field  specified for Investigators within  the 
EDC platform. For solicited injection site reactions, the relationship to study vaccine will be automatically recorded to be probably related, however, the Investigator will determine the relationship for each systemic solicited reaction.  
Symptoms continuing beyond the solicited AE collection period (7 days following each injection)  will be collected  and recorded  as an unsolicited  AE in the electronic source document 
(eSD).  
5.12 Unsolicited  Adverse Events  
 
Unsolicited AEs (any AEs not listed in the diary) will be collected for this study. Details regarding definitions, evaluation, reporting periods, and documentation are outlined in Section  7. 
5.13 Prior and Concomitant Medications  and Procedures  
 
At the Screening  visit,  the details  of prior and concomitant  medications  and procedures (through 
30 days prior to Day 1) usage will be collected, including history of vaccinations. From Day [ADDRESS_466382] received  or be planning to  receive:  
 
• Licensed  or investigational pneumococcal (pneumonia) vaccine.  
• Investigational agents  or study product from  30 days prior to Day 1 through the duration 
of the study. 
• Other  (non-pneumococcal) licensed  vaccines  from  30 days prior to Day 1 through 
Day 29. 
• Blood or blood product (including IGIV)  from  90 days prior to Day 1 through the 
duration of the study. 
• Systemic  immunosuppressant therapy  (eg, chemotherapeutics)  and immunostimulants.  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  39 of 67 
  
 • Immunomodulatory medications  (eg, oral corticosteroids) from  30 days prior to Day 1 or 
received systemic corticosteroids exceeding physiologic replacement doses within 
14 days prior to study vaccination  through Day  29. 
 
The history of all prohibited medications  at any time during study participation  (regardless  of 
association with an AE) will be collected.  
5.[ADDRESS_466383] notify the Medical Monitor (and as backup, Medical Director) no later than [ADDRESS_466384]’s source documents. The Sponsor will review all protocol deviations on 
an ongoing basis and will be responsible for categorizing protocol deviations as exclusionary or not. 
5.[ADDRESS_466385] report  any error  in the dosing of study vaccine to the 
site-assigned unblinded CRA and Medical Monitor or designee within 24 hours of the 
Investigator’s awareness  of the error.  Additional information regarding the dosing error may be 
provided as a follow-up report. A dosing error without signs or symptoms is not considered an AE but may be determined to be an important protocol deviation and investigated further. 
5.18 Study  Completion: For Individual  Subjects  
 
An individual subject  is considered to complete  study participation  after completion  of the 
Day [ADDRESS_466386]  stops study 
participation before the Day 180 visit. 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466387] (but cannot require) such subjects to provide the 
reason(s) for withdrawal of consent and to undergo an Early Discontinuation visit. 
 
In addition, the Investigator, at his or her discretion, may withdraw a subject from  further 
participation in the study. Criteria for withdrawal by [CONTACT_11584]: 
• Noncompliance with the protocol  
• Pregnancy  
• Immediate  hypersensitivity reaction  associated  with a study injection  
• Loss  to follow-up – requires  documentation of  at least  [ADDRESS_466388]’s projected 
last visit.  
• Other  reason(s) which, in  the opi[INVESTIGATOR_689], indicates  that continued 
participation in the study is not in the best interest of the subject. 
 
The Investigator or designee must report  any early  discontinuation for safety  reasons  to the 
Medical Monitor or designee within [ADDRESS_466389]  at the Sponsor’s discretion. 
Subjects who undergo Early Discontinuation after study vaccination will not be replaced. 
5.21 Study  Completion:  Overall  
 
The study is planned to be completed  after all subjects  have completed  the Day  180 (Month 6) 
visit (or Early Discontinuation, as appropriate), all necessary safety follow-up has been 
completed, and all data have been monitored and queries have been resolved. The Sponsor reserves the right to terminate the study prior to the planned study completion. 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  42 of 67 
  
 • Urine  pregnancy  test (females  of childbearing potential)  
• Prior and concomitant medications  
• Randomization  
 
All eligible,  consented, and randomized  subjects  will be vaccinated at  the Day  1 Baseline visit.  
 
• Study vaccine administration,  either  VAX -[ADDRESS_466390] during the visit and  after  study vaccine administration:  
 
• Acute observation for at least  30 minutes  after  vaccine administration  
• Vital signs collected  at least  30 minutes  after  vaccine administration  
• AE (solicited  and unsolicited) and SAE  evaluation  
• Concomitant medications  
• Instructions on completion  of an electronic  diary, use  of a ruler  and thermometer  
6.1.3 Day 8 (+3 days)  
 
The following procedures will take place  at this visit: 
 
• Visual  inspection of injection  site location  
• Review  of diary  data with the subject;  Investigator’s assessment  of severity  and 
relationship to study vaccine 
• Concomitant medications  
• AE (solicited  and unsolicited) and SAE  evaluation  
6.1.4 Day 15 (+3 days)  
 
This visit is a follow-up phone call for safety  evaluation. The following procedures will take 
place at this visit: 
• Concomitant medications  
• AE (unsolicited) and SAE  evaluation  
6.1.5 Day 29 (± 3 days)  
 
The following procedures will take place  during this  visit:  
 
• Concomitant medications  
• AE (unsolicited) and SAE  evaluation  
• Biological specimen  collection  for clinical  laboratory tests:  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466391],  regardless  of the 
suspected causal relationship with study vaccine. 
 
The definition  of an AE includes:  
 
• A new-onset symptom or disease  
• An exacerbation  of a pre-existing  symptom or disease  
• A new-onset laboratory abnormality  considered  by [CONTACT_210699]  
• A new-onset symptom or disease that occurs as a result  of a protocol- specified  procedure 
The definition of an AE does not include: 
• A pre-existing  symptom or disease  that does not worsen  during the study (even  if first 
disclosed by [CONTACT_210700]) 
• A medical or surgical intervention such as surgery, endoscopy, tooth extraction, or 
transfusion (although the condition leading  to the procedure or a complication  from  the 
procedure may be an AE) 
• An uncomplicated  pregnancy  
• A dosing error without any  resulting  signs or symptoms  
• Any other situation  where  an untoward medical  occurrence has not occurred (eg, 
hospi[INVESTIGATOR_210662])  
 
The definition  of a treatment emergent  AE (TEAE)  is an event  that occurs  after  vaccination  and 
within the 28 days after vaccination (ie, excluding those after a subject has given informed 
consent, but before vaccination). 
 
The definition of a NOCI  includes:  
 
A new-onset of chronic illness  is a disease or condition, that is newly  diagnosed, requires 
ongoing medical attention and/or limits activity of daily living, eg, heart disease, cancer, diabetes.  
 
The Investigator will attempt to establish a diagnosis based on signs, symptoms, and other 
clinical  information. Whenever  possible, the Investigator will report  an AE as a diagnosis rather 
than one or more  signs or symptoms. If a clinically  significant laboratory abnormality  meets  the 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466392] during a protocol-specified time period. Solicited AEs for this study are local 
events  of pain, erythema (redness)  and edema (swelling)  at the injection  site, and systemic  events 
of fever (oral temperature ≥ 100.4ºF), fatigue, headache, muscle pain, and joint pain. 
7.1.[ADDRESS_466393] or discovered by [CONTACT_3786]. New onset of chronic illness(s) would be recorded as part of the collection of unsolicited  AEs as specified  in the visit procedures. Unsolicited  AEs will be collected  separately 
from solicited AEs.  
7.1.4 Serious  Adverse Event  
 
An SAE  is an AE (either solicited  or unsolicited) which meets  any of the following criteria:  
 
• Results  in death  
• Is life-threatening  
• Requires  hospi[INVESTIGATOR_372815]  
• Results  in a persistent  or significant incapacity  or substantial disruption of the ability  to 
conduct normal life functions 
• Is a congenital anomaly or birth  defect  
• Important medical  event  that may jeopardize the patient  or subject  and/or may require 
medical or surgical intervention to prevent one of the above outcomes 
 
The Investigator will evaluate all AEs for seriousness using the above criteria.  
 
“Life-threatening” means  that,  in the opi[INVESTIGATOR_689], the subject was at immediate 
risk of death from the event as it occurred. It does not mean that the event might have caused death had it occurred in a more severe form.  
 
Hospi[INVESTIGATOR_372816] a pre- existing  condition that did not 
worsen during the study is not considered an SAE. 
 
Important medical  events  may be considered  serious  at the discretion  of the Investigator.  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  47 of 67 
  
  
 
7.2 Severity  Grading  
 
The Investigator will grade all AEs for severity. AEs listed in the Guidance for Industry, 
Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive 
Vaccine Clinical Trials,  September  2007 will be graded  according to the criteria  in the table . AEs 
not listed in the Toxicity Grading Scale will be graded as follows: 
• Mild  (Grade  1) – No  interference with  activity  
• Moderate (Grade 2) – Some interference  with activity  
• Severe (Grade  3) – Significant; prevents daily  activity  
• Potentially  Life-Threatening  (Grade  4) – ER visit or hospi[INVESTIGATOR_059]  
7.3 Causality Assessment  
 
The Investigator will assess all AEs,  including solicited  AEs,  for causality  (relationship  to study 
vaccine), assigning one of these three categories: Not Related, Possibly Related, or Probably Related.  
 
An AE will be considered “Not  Related” to study vaccine  if any of the following conditions are 
met: 
• An unreasonable temporal relationship between administration of the study vaccine and 
the onset of the AE (eg, the event  occurred  either  before,  or too long after,  administration 
of the study vaccine for it to be considered related); 
• A causal  relationship  between  the study vaccine and the AE is biologically  implausible 
(eg, injury as a passenger in an automobile accident); 
• A clear  alternative  causality  for the AE is present  (eg, typi[INVESTIGATOR_372817] a 
concomitant medication).  
 
An AE will be considered “possibly related” if there is a reasonable possibility  that the AE may 
have been caused by [CONTACT_106365]. 
• A single occurrence  of an event  that is uncommon and  known to  be strongly associated 
with vaccine exposure (eg, angioedema, hepatic injury, Stevens-Johnson Syndrome) 
• One or more  occur rences of  an event  that is not commonly associated  with vaccine 
exposure, but is  otherwise uncommon in  the population exposed to  the vaccine (eg, 
tendon rupture) 
• An aggregate analysis of specific events observed in a clinical trial (such as known consequences of the underlying disease or condition under investigation or other events that commonly occur  in the study population independent of vaccine administration)  that 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  48 of 67 
  
 indicates  those events  occur more frequently in the vaccine treatment  group than in a 
concurrent or historical control group 
 
An AE will be considered “Probably related” if there is evidence that the AE  was caused  by [CONTACT_106957]. 
7.[ADDRESS_466394] the Investigator (or 
designee)  immediately.  All subjects  experiencing  an SAE  will be evaluated  by [CONTACT_372845]. In the event of a 
fatal SAE, the Investigator must provide the Sponsor with any available post-mortem findings, 
including histopathology. 
 
Additionally, the Sponsor may request  that the Investigator perform  or arrange for the conduct of 
supplemental investigations for one or more AEs. 
7.5 Reporting  of Adverse  Events  
7.5.1 Reporting  Periods  
 
The four reporting periods for solicited AEs begin immediately after study vaccine 
administration and continue for 7 days after the injection. The reporting period for unsolicited AEs is immediately after study vaccine administration on Day 1, continuing through Day 29. 
AEs that correspond to solicited AE terms but occur outside of (or continue past) the solicited AE collection periods are also collected through the unsolicited AE reporting periods. The reporting period for SAEs  begins at the time of informed consent and continues for the duration 
of study participation. 
 
A summary  of the reporting periods is presented  in Figure 3 . 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466395]’s  source documents and 
solicited AEs into the source document file within 24 hours of awareness. 
 
All AEs  should include:  
 
• Event term 
• Start  and stop date  
• Severity  
• Seriousness (Yes/No)  and if Yes, which  Seriousness  criteria were  met 
• Relationship  to Study Vaccine  
• Action  taken  in response to the AE 
• Action  taken  with  Study Vaccine  
7.[ADDRESS_466396] also enter SAEs into the eSD.  
 
E-mail transmission  of the SAE  Report Form  is the preferred  method to transmit thisinformation 
to the Vaxcyte Clinical Safety Team. If initial notification is provided via telephone, this does  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466397] the need  for the investigator to complete  and sign the SAE  Report  Form  within  the 
designated reporting time frames.  
 
Communication Methods  to the Vaxcyte Clinical Safety  Team:  
 
E-mail (primary):  [EMAIL_7200]  
 
Telephone  (emergency):  1 (650) 275- [ADDRESS_466398] include an alternate causality.  
 
In order  to avoid delays  in initial reporting, additional information  regarding the SAE  may be 
provided as a follow-up report. The Investigator may also modify the diagnosis, seriousness, and/or causality assessment based on this information. 
 
Vaxcyte will notify the Investigator of SAEs that meet criteria for expedited reporting to regulatory authorities.  The Investigator is responsible for notifying the applicable IRB  of these 
events and adhering to any other applicable local reporting requirements. 
 
The Sponsor will report AEs to FDA in accordance with 21 CFR 312.32. Specifically, the Sponsor will report  unexpected  fatal or life-threatening  suspected  adverse reactions  no later than 
7 days after initial receipt of the information, and serious and unexpected suspected adverse reactions (S[LOCATION_003]Rs) no later than 15 calendar days after determining that the information qualifies for expedited reporting. 
 
It is also the responsibility  of Vaxcyte to make the determination  of which  SAEs  are S[LOCATION_003]Rs,  as 
defined in 21 CFR 312.32. 
• Suspected  adverse reaction  means  any AE for which  there is a reasonable possibility  that 
the drug caused the AE. 
• Unexpected  adverse reaction  means  an AE that is not listed  in the Investigator’s 
Brochure or is not listed at the specificity or severity that has been observed. 
 
All S[LOCATION_003]Rs,  as agreed  upon by [CONTACT_9533], will be reported  to FDA.  S[LOCATION_003]Rs  will be 
provided to all participating Investigators. 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466399] of two persons (independent Subject Matter Experts) and an unblinded statistician  to compi[INVESTIGATOR_372818].  The DMC  will independently review 
the [ADDRESS_466400]-vaccination unblinded safety data for the subjects aged 18 to 49 years before 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  52 of 67 
  
 advancing the study into the older adult population. Stoppi[INVESTIGATOR_372819] (see Section  7.10) and the DMC  will conduct ad hoc 
reviews if the study is paused, triggered by [CONTACT_210702][INVESTIGATOR_1869], in order to identify any emerging safety concerns. 
 
The DMC  will refer  to the DMC  Charter  for procedures.  
 
7.10 Study  Stoppi[INVESTIGATOR_372820] 18 to 49 and 50 to 64 years in the Phase 1 and Phase 2 segments of the clinical study, respectively. During the vaccination period(s), if any of the stoppi[INVESTIGATOR_47940], no further administration of study vaccine(s) will occur until safety data are reviewed by [CONTACT_372846], as needed. Study dosing may be resumed if the DMC 
determines  it is safe to proceed  with no modifications or with modifications  to the protocol plans. 
 
Phase 1: Subjects  aged  18 to 49 years  
 
• One (1) SAE  regardless  of relationship  
• One (1) or more  subjects with a Grade 4 (potentially  life threatening) assessed  as at least 
possibly related to investigational product 
• Three  or more subjects  with a Grade  3 (severe)  AE assessed  as at least possibly related  to 
investigational product 
 
Phase 2: Subjects  aged  50 to 64 years  
 
• One (1) SAE  assessed  as at  least  possibly related  to investigational product  
• One (1) or more  subjects with a Grade 4 (potentially  life threatening) assessed  as at least 
possibly related to investigational product 
• Two or more  subjects  with the same or similar  Grade  3 (severe)  AE, including laboratory 
abnormalities, assessed as at least possibly related to investigational product other than 
solicited events  
• Eight (8) or more  subjects  with  the same or similar  Grade 3 (severe)  solicited AE  
 
The appropriate regulatory authority will be informed  in writing  when  either  of the following 
occurs:  
• Study dosing is stopped 
• DMC  has decided  to resume or discontinue study activities  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  53 of 67 
  
 Enrollment may be resumed  following review  of available safety  data by [CONTACT_1034].  
 
Vaxcyte clinical  safety  team  will refer to the VAX24 -102 Safety  Medical  Monitoring Plan for 
detailed procedures on stoppi[INVESTIGATOR_372821]. 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466401] identity information will be maintained for 15 years unless a longer period is required by [CONTACT_65855]. 
8.3 Data  Monitoring  
 
The Sponsor or designee will monitor completed  eSD at regular  intervals  throughout the study to 
verify adherence to the protocol; completeness, accuracy, and consistency of the data; and 
adherence to local regulations on the conduct of clinical research. The Investigator must make hard copy source documentation accessible to the Sponsor or designe e as needed to verify the 
information in the eSD. The Investigator agrees to cooperate with the Sponsor or designee to ensure that any problems detected in the cou rse of data monitoring are resolved. 
8.[ADDRESS_466402]- vaccination  within  a validated  system  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466403] permit the Sponsor and/or designee,  regulatory agencies,  and/or the IRB 
direct access to facilities and study documentation for the purpose of auditing study conduct. Direct  access  includes examining, analyzing, verifying, and reproducing any records  and reports 
that are needed for the evaluation of the study. 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  56 of 67 
  
 9 STATISTICAL  ANALYSIS  
 
This Phase 1/2a study is designed to  achieve both safety  and immunogenicity  objectives.  
 
The primary objectives are to evaluate the safety of a single injection of VAX-24 at three dose 
levels, and to compare the safety of VAX -24 to that of PCV20 administered to two control 
groups: 1) subjects  18 to 49 years  of age receiving  PCV20; and 2) subjects  50 to 64 years  of age 
receiving PCV20. 
 
The secondary immunogenicity  objectives  are to assess the induction of OPA and IgG antibody 
responses by [CONTACT_210705] -24 at three dose levels compared to the 20 PCV20 serotypes (1, 3, 4, 5, 6A, 
6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F), as measured at 
28 days after  the injection  (Day  29) and  4 non- PCV20  serotypes (2,  9N, 17F,  20B), measured  at 
28 days after the injection (Day 29) for subjects aged 50 to 64 years. 
 
Endpoints will be analyzed  by [CONTACT_551] (18 to 49, 50 to  59, 60 to  64, and  50 to  64 years  of age). 
Safety will also be summarized for all subjects combined (18 to 64 years of age). 
 
A statistical analysis  plan will be generated  and approved prior to the data freeze and treatment 
group unblinding for the primary  safety  and secondary  immunogenicity  endpoints through Day 
[ADDRESS_466404] Month 6 visits and final database lock. A single completed Clinical Study Report (CSR) will summarize safety findings through Month 6 for all 864 subjects and immunogenicity for 800 
subjects 50 to 64 years of age. 
9.1 Sample  Size Calculation  
 
For subjects  18 to 49 years  of age, sample  size is not driven by [CONTACT_372847]. With 16 subjects, events 
that occur at a frequency of 15% or more will be detected with at least 92% probability and events that occur at a frequency of 10% or more will be detected with 81% probability. Therefore  [ADDRESS_466405] safety assessment. 
 
For subjects  50 to 64 years  of age, sample  size is not based  on statistical justification.  A total of 
800 subjects should provide sufficient information to assess safety and immunogenicity in the 50 to 59 and 60 to 64 age groups. The sample size will also be adequate to plan future studies. 
9.2 Treatment  Period  
 
The Treatment period begins at the time of study vaccine administration and extends through the 
Day 29 visit.  The Follow-up period spans the  time following the Day  29 visit through Day  180 (6 
months after study vaccine administration). 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  57 of 67 
  
 9.3 Treatment  Groups  
 
Subjects  will be randomized  into 8 treatment  groups as  displayed in Table 4 . 
 
Table 4 Treatment  Groups  
 
 
 
Treatment 
Group   
 
 
Age Cohort   
 
 
N Treatment Administered  
(VAX- 24, mcg Total  PS/dose  per serotype; 
PCV20)  
Day 1 
1 18 to 49  16 VAX-24, 1.1 mcg 
2 18 to 49  16 VAX-24, 2.2 mcg 
3 18 to 49  16 VAX-24, 2.2/4.4 mcg 
4 18 to 49  16 PCV20  
5 50 to 64  200 VAX-24, 1.1 mcg 
6 50 to  64 200 VAX -24, 2.2 mcg 
7 50 to  64 200 VAX -24, 2.2/4.4  mcg 
8 50 to  64 200 PCV20  
Total   864  
 
9.4 Populations for Analysis  
 
Randomized Population: All screened subjects who provide informed consent, provide 
demographic and other Baseline Screening  measurements,  are randomized, and  are assigned  a 
study subject ID (number). Each subject will be analyzed as randomized (ie, according to the 
vaccine regimen to which the subject was randomized). 
 
Exposed Population:  All subjects  who receive at least one study vaccination.  
 
Safety  Population: All subjects  in the Exposed Population who provide safety  assessment  data. 
This generally includes any subjects not lost to follow-up at Day 1, as they will be at risk for reporting an SAE.  Each  subject  will be analyzed  as treated  (ie, according to the vaccine  regimen 
a subject received, rather than the vaccine regimen to which the subject may have been randomized).  
 
Immunogenicity Evaluable Population: For this Phase 1/2 study, the immunogenicity population will be analyzed as treated (ie, according to the vaccine regimen a subject receives, which may be different from the vaccine regimen to which the subject is randomized in the case of treatment errors).  The Phase 1 subjects  aged  18 to  49 years  are not included  in this population. 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  58 of 67 
  
 The Immunogenicity Evaluable Population (IEP)  includes all  subjects  in the Exposed Population 
who:  
• Have no major  protocol deviation  that would impact immunogenicity  assessment  or other 
reason to be excluded as defined prior to unblinding or analysis. 
• Have not received  a prohibited medication  or vaccine.  
• Provide evaluable serum  sample  results  for baseline,  the relevant  post- vaccination  time 
points, and within the required time frames: 
o Baseline:  Day  1 or within  30 days before  study vaccine administration  
o Day 29: Day  [ADDRESS_466406] deviation, median, minimum, and maximum. 
The frequencies  and percentages  of subjects  by [CONTACT_4321], race,  and ethnicity  will be presented.  
 
Demographic data will be tabulated  for the Randomized,  Immunogenicity Evaluable,  and Safety 
Populations.  
9.6 Safety  Analysis  
 
All safety  analyses will  be based  on the Safety  Population.  
 
9.6.1 Analysis of Extent  of Exposure  
 
The frequencies  and percentages  of subjects with  vaccinations  will be summarized  by [CONTACT_210707]. 
9.6.2 Solicited  AEs 
 
With  the exception  of redness  and swelling,  all solicited  AEs (local  and systemic)  will be 
summarized according to severity grading scales defined in Section 7.2, from “mild” to 
“potentially life -threatening.” 
 
Solicited  AEs will be recorded  daily  until [ADDRESS_466407]-injection  within  an electronic diary. The 
analyses of solicited AEs (any event, after any injection, and after each injection) will be performed by [CONTACT_210708]. In addition, solicited AEs ongoing after [ADDRESS_466408]- injection will also be recorded as unsolicited AEs.  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  59 of 67 
  
 Frequencies and percentages of subjects experiencing each solicited AE will be presented by 
[CONTACT_764].  Summary  tables  showing the occurrence of any local  or systemic  solicited 
AE overall and at each time point will also be presented. 
 
The severity of redness and swelling recorded as diameters (cm) will be summarized according  
to categories  based  on the largest  diameter  linear  measurement  when  the local  reaction  is present:  
• Grade 0/absent: 0 - 2.4 cm  
• Grade 1/mild: >  2.5 - 5.0 cm. 
• Grade 2/moderate: > 5.1 - 10.0 cm.  
• Grade 3/severe:  > 10.0 cm.  
 
The following summaries  of subjects  will be performed:  
 
• Solicited  events  by [CONTACT_210709]- injection,  for each event  and for any  event.  
• Time  of first onset of solicited  AEs,  after  injection,  for each event  and any event.  
• Solicited  AEs by [CONTACT_372848],  after injection,  for each event  and for any 
event.  
• Duration of solicited  AEs,  after injection,  for each event  and maximum duration of any 
event.  
• Solicited  AEs,  occurrence of at least one event  by [CONTACT_17203]  (local,  systemic),  after 
injection.  
 
For each  of the time  points or time  intervals  presented  in the summaries,  only subjects  with  at 
least one observation (ie,  any non- missing  values  but excluding “Not  done/unknown”) for the 
solicited AEs will be summarized.  
9.6.3 Unsolicited  AEs 
 
All the unsolicited  AEs occurring during the study will be recorded,  regardless  of their 
assessment of relatedness by [CONTACT_737].  
 
The original verbatim  terms  used by [CONTACT_372849]. The unsolicited AEs will then be grouped by [CONTACT_91357] (SOC). All reported AEs, as well as AEs judged by [CONTACT_210712], will be summarized by [CONTACT_1570], according to SOC and preferred term within SOC. When an unsolicited AE occurs more than once for a subject, the maximum severity reported and strongest reported relationship to the treatment group will be counted. 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  60 of 67 
  
 Only  TEAEs  will be summarized  as defined in Section  7.1.1. The selection  of unsolicited  AEs 
and their assignment to time intervals will be done by [CONTACT_210713]/persisting.  
 
Unsolicited  AEs will be summarized  by [CONTACT_372850]:  
 
• Any unsolicited  TEAE  
• Possibly or probably related  unsolicited  TEAEs  
• SAEs  
• Possibly or probably related  SAE  
• Unsolicited  TEAE leading  to withdrawal  
• Any AE leading  to death  
 
Listings  of all TEAEs  will be provided by [CONTACT_1130].  
 
9.6.4 Combined  Solicited  and Unsolicited  AEs 
 
Solicited AEs continuing beyond 7 days after any injection will be coded by [CONTACT_372851].  An overall  summary  of subjects  with all combined solicited 
and unsolicited AEs, by [CONTACT_9315], will be provided as well.  
9.6.5 Analysis of Other Safety  Data  
 
The frequencies  and percentages  of concomitant medications  will be tabulated  by [CONTACT_551], 
treatment group, and overall. Medications will be coded using the WHODRUG dictionary. 
9.7 Immunogenicity  Analysis (50 to 64 years)  
 
9.7.1 GMT/GMR  
 
Immunogenicity analyses  will be performed  by [CONTACT_551] (50  to 59 and 60 to  64) and overall  
(50 to 64 years).  Analyses will be performed  for both OPA titers  (log 10) and IgG titers  (mcg/mL). 
All immunogenicity analyses will be based on the IEP and Exposed Population. 
 
The GMTs and GMCs will be analyzed via linear models. The primary model is an analysis of 
variance (ANOVA),  with logarithmically -transformed  titers  (log 10) as the dependent variable and 
treatment group and study site as the fixed effects in the model. The results included in the main 
tables  of this report  will be based  on this basic ANOVA model. As a secondary  analysis,  in order 
to remove the effect of baseline concentration on the GMTs, an analysis of covariance 
(ANCOVA) will also be performed. The ANCOVA includes treatment group and study site as 
the fixed effects and log 10 baseline titer as the covariate in the model. The rationale for including  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466409] squares means and their 95% confidence intervals (CIs) calculated based on the 
ANOVA and ANCOVA will be back  transformed  and reported  as the group GMT  and GMC 
values (adjusted for the mean baseline in the case of the ANCOVA). GMRs will also be calculated from the ANCOVA and ANOVA models.  
 
Comparisons between relevant groups will be based on the estimated adjusted GMTs measured at Day 29 for 24 serotypes in VAX-24 (of those 20 in  PCV20), and mean  square error calculated 
from the basic ANOVA model using contrast statements. The analysis of GMFR relative to  
Day [ADDRESS_466410]  will be the three  VAX-24 dose levels  group versus the PCV20 
(20 serotypes) group. However, the three VAX-24 dose groups will also be compared in a pairwise  fashion on a serotype by [CONTACT_372852].  No adjustment for multiplicity  will be applied 
and missing data will not be imputed. 
9.7.2 Threshold  analyses  
 
For the 4 non- PCV20  serotypes that are in VAX-24, the % of subjects  with a  ≥ 4-fold increase in 
OPA titer will be evaluated using a logistic regression model, with an indicator variable for 
achieving a ≥ 4-fold increase in OPA titer as the dependent variable, and treatment group and 
study site as fixed effects and log 10 baseline titer as a covariate. The difference in proportions 
achieving a ≥ 4- fold increase in OPA titer in each of the three VAX -24 dose levels group versus 
the PCV20 and the corresponding 95% CIs will be calculated. If the lower bound of the 95% CI 
is > 0.1, the VAX-24 dose will be deemed statistically superior to PCV20. 
The percentage of subjects achieving specified thresholds (eg, GMFR ≥ [ADDRESS_466411] serotype- specific LLOQ of the assay), and 
associated  Wilson  (score)  95% CI, will be calculated  for the Day 29 visit data for each  treatment 
group. A reverse cumulative distribution curve will be provided. Differences between pair- wise 
treatment groups may be determined via Fisher’s exact tests.  
9.[ADDRESS_466412], the study will resume enrollment of subjects aged 50 to 64 years. 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466413]  of the  Study  
 
The study will be performed  in accordance with the protocol and consistent  with ICH GCP 
Guidelines and applicable local regulatory requirements and laws. 
10.2 IRB Oversight  
 
The study (protocol, informed  consent form,  recruiting  materials,  and any documents seen by [CONTACT_1560]) will be reviewed and approved by [CONTACT_210717]. Subjects will 
not be recruited, consented, screened, or enrolled until the IRB has approved the required documentation. In addition, the IRB will review amendments to the protocol before their implementation.  
 
The Investigator will retain  all correspondence with the IRB in the trial master  file and forward 
copi[INVESTIGATOR_210671]. 
10.3 Informed  Consent  
 
The Sponsor or  designee will provide a master ICF  template  to each site for development of a 
site-specific  ICF. At the Investigator’s discretion, the site may develop  a separate  ICF for pre- 
screening as described in Section 5.2. 
 
All site -specific ICFs must be approved by [CONTACT_210718], local regulatory requirements, and legal requirements. The Sponsor 
or designee will advise the Site of required changes to the master  ICF template  during the course 
of the study. 
 
The Investigator will ensure that each potential study subject  is fully  informed about the nature 
and objectives of the study and possible risks associated with participation. Before informed consent is obtained, the Investigator, or a qualified person designated by [CONTACT_737], will provide the potential study subject  with ample  time and opportunity to inquire about the details 
of the trial, and will answer all relevant questions to the potential study subject’s satisfaction. The potential study subje ct will then decide whether or not to participate in the trial. The 
Investigator, or a qualified person designated by [CONTACT_737], will obtain written informed consent from each study subject before any study- specific activity is performed.  
 
The Investigator will retain  the original and  any amended  signed and  dated  Informed  Consent 
Form(s) at the study site and provide a copy to each study subject. 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466414]’s anonymity is maintained. In all documents 
submitted  to the Sponsor and/or its designee,  subjects can be identified  by [CONTACT_372853]. Documents not intended for submission to the Sponsor and/or its designee (eg, signed 
ICFs)  must be maintained  by [CONTACT_372854]. 
10.5 Compensation for  Injury  
 
The Sponsor will adhere to local  regulations and guidelines regarding clinical trial compensation 
to subjects whose health is adversely affected by [CONTACT_111621]. The applicable policy 
for compensation for injury will be described in the master ICF template.  
10.6 Clinicaltrials.gov  
 
For purposes of reporting to clinicaltrials.gov,  the Sponsor is the responsible party  and will 
provide information regarding this study in accordance with applicable regulations. 
10.7 Public  Disclosure and Publication  Policy  
 
All publication rights are delineated  in the Clinical Study Agreement  with the Investigator(s).  
 
10.[ADDRESS_466415] to study subjects. In that event, the Sponsor will notify the IRB in writing within 7 calendar days after the implementation.  
 
Amendments, including descriptions and rationales,  will be documented in this section  of the 
protocol.  

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  [ADDRESS_466416] Additional Serotypes and Discovery of Serological 
Subtypes in Streptococcus pneumoniae Serotype 20. Clin Vac Immunol. 2012;12(6):835-841. 
 
Choe S, Bennett  MJ, Fujii  G, et al. The crystal  structure  of diphtheria toxin. Nature. 
1992;357(375):[ADDRESS_466417] C- A. Glycoconjugate vaccines  and immune  interference:  A review. 
Vaccine. 2010;28(34):5513-5523. 
 
Diethelm- Okita  BM, Okita  DK, Banaszak  L, Conti- Fine BM. Universal  epi[INVESTIGATOR_372822]4+ cells on tetanus and diphtheria toxins. J Infect Dis. 2000;181(3):1001–1009. 
 
Feyssaguet M, Bellanger A, Nozay F, et al. Comparison between a new multiplex electrochemiluminescence assay  and the WHO reference enzyme-linked immunosorbent assay  to 
measure serum antibodies against pneumococcal serotype- specific polysaccharides. Vaccine.  
2019;37(16); 2208- 2215.  
 
Gierke,  R, Wodi AP, and Kobayashi M. Epi[INVESTIGATOR_372823] -Preventable 
Diseases. E -Book: The Pi[INVESTIGATOR_45508], Pneumococcal Disease. 2015. 
 
Gierke, R. Current Epi[INVESTIGATOR_372824], [LOCATION_002]-2019 updates. Presented  to the Advisory Committee  on Immunization  Practices,  25 June 2021. www.  cdc.gov/ 
vaccines/acip/ meetings/downloads/slides-2021-06/02- Pneumococcal -Gierke-508.pdf, accessed 
28 September 2021. 
 
Goldblatt D, Ashton L, Zhang Y, et al. Comparison of a New Multiplex Binding Assay versus the Enzyme-Linked Immunosorbent Assay  for Measurement  of Serotype- Specific  Pneumococcal 
Capsular Polysaccharide IgG. Clin Vaccine Immunol. 2011;18(10):1744-1751. 
 
Jackson  L, Neuzil  K, Nahm  M, Whitney  C, et al. Immunogenicity of varying dosages of 7- valent 
pneumococcal polysaccharide–protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2007;25(20): 4029-4037. 
 
Marchese RD, Puchalski D, Miller P, et al. Optimization and validation of a multiplex, 
electrochemiluminescence- based  detection  assay  for the quantitation  of immunoglobulin G 
serotype-specific antipneumococcal antibodies in human serum. Clin Vaccine Immunol. 
2009;16:387 –396. 
 
Matanock  A, Lee G, Gierke R, et al. Use of 13- Valent  Pneumococcal  Conjugate Vaccine  and 23- 
Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated 
Recommendations of the Advisory Committee on Immunization Practices. Morb Mortal Wkly Rep. 2019;68(46):1069-1075. 

Protocol  VAX24 -101, V4.0,  31-May -2022  
VAX -24; Vaxcyte,  Inc. Page  65 of 67 
  
 Nolan  KM, Bonhomme ME, Schier  CJ, et al. Optimization  and validation  of a microcolony 
multiplexed opsonophagocytic killing assay for 15 pneumococcal serotypes. Bioanalysis. 
2020;12(14):1003- 1020.  
 
Package  Insert.  Prevnar  20™ (pneumococcal 20- valent  conjugate vaccine).  Manufactured  by 
[CONTACT_372855], Philadelphia PA. Accessed at https:// www.prevnar20.com/  
 
Ramirez JA, Wiemken  TL, Peyrani  P, et al. University  of Louisville  Pneumonia Study Group. 
Adults Hospi[INVESTIGATOR_372825]: Incidence, Epi[INVESTIGATOR_623], and 
Mortality. Clin Infect Dis. 2017;65(11):1806-1812. 
 
Raju  R, Navaneetham  D, Okita  D, Diethelm- Okita  B, McCormick  D, Conti- Fine BM. Epi[INVESTIGATOR_372826]4+ cells on diphtheria toxin: structural features of sequence segments forming epi[INVESTIGATOR_210675]. Eur J Immunol. 1995;25(12):3207-3214. 
 
US Centers  for Disease Control and Prevention, ABCs  Report: Streptococcus pneumoniae, 2018, 
https://www.cdc.gov/abcs/reports-findings/survreports/spneu18.html , accessed [ADDRESS_466418] 2021. 
 
US Centers for Disease Control and Prevention, Clinical Features of Pneumococcal Disease, https://www.cdc.gov/pneumococcal/clinicians/clinical- features.html,  accessed  [ADDRESS_466419] 2021. 
 
US Department of Health and Human Services. Food and Drug Administration. Center for 
Biologics Evaluation and Research.  Guidance for Industry. Toxicity  Grading  Scale for Healthy 
Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. September 2007.  
 
US Food and Drug Administration. Prevnar 13 (Pneumococcal 13- valent Conjugate Vaccine 
(Diphtheria CRM197 Protein)):  Approval History, Letters,  Reviews,  and Related  Documents. 
2015. Available  online at https://www.fda.gov/vaccines-blood-biologics/vaccines/prevnar-13, 
updated on [ADDRESS_466420] 2021. 
 
US Food and Drug Administration. Prevnar 20 (Pneumococcal 20- valent Conjugate Vaccine 
(Diphtheria CRM197 Protein)):  Approval History, Letters,  Reviews,  and Related  Documents. 
2021. Available  online at https://www.fda.gov/vaccines-blood-biologics/vaccines/prevnar-20, 
updated on [ADDRESS_466421]. 2020;26(4):512.e1-512.e10. 
